Quick summary
Orforglipron is Eli Lilly's oral, once-daily, non-peptide small-molecule GLP-1 receptor agonist. It has completed Phase 3 trials for obesity and type 2 diabetes and is not yet FDA-approved, with global regulatory submissions filed in 2025 to 2026.
Overview
Orforglipron (LY3502970) is an oral, once-daily, non-peptide small-molecule GLP-1 receptor agonist developed by Eli Lilly (originally discovered by Chugai Pharmaceutical). Unlike injectable peptide GLP-1 agents such as semaglutide or liraglutide, orforglipron is a small molecule taken by mouth with no food or water restrictions, eliminating injection burden. It has completed multiple Phase 3 trials demonstrating significant weight loss and glycemic improvements.
Mechanism of action
Orforglipron acts as a full agonist at the GLP-1 receptor (GLP-1R) through a non-peptide binding mode. It engages the GLP-1R transmembrane domain rather than the extracellular peptide-binding cleft used by native GLP-1 and peptide analogs. Receptor activation stimulates glucose-dependent insulin secretion from pancreatic beta cells, suppresses glucagon release from alpha cells, slows gastric emptying to reduce postprandial glucose excursions, and engages hypothalamic satiety circuits to reduce appetite and caloric intake. Because it is a small molecule, orforglipron is orally bioavailable (~30-40%) and does not require the enteric absorption protections (SNAC excipient, tablet formulation, empty stomach requirements) used by oral semaglutide. CYP3A metabolism supports a half-life of 25-68 hours compatible with once-daily dosing.
Dosing protocols
| Purpose | Route | Dosage | Frequency | Notes |
|---|---|---|---|---|
| Obesity / weight management (Phase 3 trials) | oral | 12–36 mg | Once daily | Titrated upward in Phase 3 trials to 36 mg once daily. Can be taken without food or water restrictions, unlike oral semaglutide. |
| Type 2 diabetes glycemic control (Phase 3 trials) | oral | 3–36 mg | Once daily | Dose titration from 3 mg upward depending on tolerability. No meal timing restrictions. |
Dosing information is for educational purposes only. Consult a qualified healthcare professional before using any peptide.
Research summary
In the ATTAIN-1 Phase 3 trial (72 weeks), orforglipron 36 mg achieved mean weight loss of 12.4% (27.3 lbs) vs 0.9% with placebo. ATTAIN-2 showed 10.5% (22.9 lbs) at 36 mg vs 2.2% placebo. ATTAIN-MAINTAIN showed orforglipron maintained weight loss in patients switching from injectable incretins (semaglutide/tirzepatide). In a head-to-head Phase 3 trial vs oral semaglutide for T2D, orforglipron delivered superior HbA1c reduction and weight loss. Lilly has filed global regulatory submissions for obesity; US diabetes submission in 2026.[1][2][3]
Evidence grading
Each claimed benefit is graded by the strength of available evidence. Grades reflect study quality, not effect size.
Strong = multiple RCTs · Moderate = limited trials or observational · Preliminary = animal or in vitro only · Insufficient = anecdotal or no published data
Side effects
Side effects vary by individual. This is not an exhaustive list. Report unusual symptoms to a healthcare professional.
Common stacks
Peptides commonly paired with Orforglipron for synergistic effects.
Legal status
Investigational new drug; Phase 3 complete, regulatory submissions filed in 2025-2026. Not yet FDA-approved as of April 2026. Expected US regulatory action for obesity in Q2 2026. Not available outside of clinical trials or expanded access programs.
Sourcing & access
Research compound
Orforglipron is classified as a research compound. Regulatory status varies by jurisdiction. Always verify current legal status and source from vendors providing third-party certificates of analysis (COA).
Frequently asked questions
Orforglipron (LY3502970) is an oral, once-daily, non-peptide small-molecule GLP-1 receptor agonist developed by Eli Lilly. Unlike injectable peptide GLP-1 agents, it is a small molecule taken by mouth without food or water restrictions.
Orforglipron acts as a full agonist at the GLP-1 receptor through a non-peptide binding mode, engaging the receptor's transmembrane domain. Activation stimulates glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and engages hypothalamic satiety circuits to reduce appetite.
No. As of April 2026, orforglipron is an investigational new drug with Phase 3 complete and regulatory submissions filed in 2025 to 2026. Lilly has filed global regulatory submissions for obesity with US regulatory action expected in Q2 2026.
In the 72-week ATTAIN-1 Phase 3 trial, orforglipron 36 mg achieved mean weight loss of 12.4% (27.3 lbs) versus 0.9% with placebo. ATTAIN-2 showed 10.5% weight loss at 36 mg versus 2.2% on placebo.
Phase 3 obesity trials titrate the dose upward to 36 mg once daily by mouth, while type 2 diabetes trials evaluated 3 mg to 36 mg once daily with titration based on tolerability. Unlike oral semaglutide, orforglipron can be taken without food or water restrictions because it is a non-peptide small molecule that does not require SNAC excipients for absorption.
Orforglipron is a non-peptide small molecule that is orally bioavailable without special absorption enhancers, while oral semaglutide is a peptide that requires the SNAC excipient, specific tablet formulation, and empty-stomach dosing. In a head-to-head Phase 3 trial for type 2 diabetes, orforglipron delivered superior HbA1c reduction and weight loss versus oral semaglutide.
Reported side effects across the ATTAIN Phase 3 program include nausea, vomiting, diarrhea, constipation, decreased appetite, dyspepsia, and fatigue. The gastrointestinal profile is consistent with the broader GLP-1 class and is generally dose-dependent, typically resolving with continued use or during the titration period from starting doses up to the 36 mg target dose.
Research references
- Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with ObesityPubMed
- Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 studyPubMed
- Orforglipron (LY3502970), a novel, oral non-peptide GLP-1 receptor agonist: Phase 1b study in people with type 2 diabetesPubMed